PreveCeutical Medical Inc Cash Flow Conversion Efficiency
PreveCeutical Medical Inc cash flow conversion efficiency. Based on the latest financial reports, PreveCeutical Medical Inc (18H) has a cash flow conversion efficiency ratio of 0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-520.46K ≈ $-608.47K USD) by net assets (€-7.39 Million ≈ $-8.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PreveCeutical Medical Inc (2016–2024)
Cash flow conversion efficiency of PreveCeutical Medical Inc from 2016 to 2024. This chart illustrates how PreveCeutical Medical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for PreveCeutical Medical Inc for real-time trading data and today's change.
PreveCeutical Medical Inc Cash Flow Conversion Ratio Explained
PreveCeutical Medical Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PreveCeutical Medical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PreveCeutical Medical Inc ranked by their cash flow conversion efficiency. Also see 18H market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REDSUN PROPERTIES GROUP
F:0RJ
|
N/A |
|
EVE Health Group Limited
AU:EVE
|
-0.242x |
|
Lithium Universe Ltd
AU:LU7
|
0.447x |
|
GRI Bio Inc.
NASDAQ:GRI
|
-0.141x |
|
PT Trimuda Nuansa Citra Tbk
JK:TNCA
|
-0.002x |
|
Pembroke VCT PLC
LSE:PEMB
|
-0.009x |
|
Future PLC
LSE:FUTR
|
0.068x |
|
Whitemud Resources Inc
V:WMK
|
0.164x |
Annual Cash Flow Conversion Efficiency for PreveCeutical Medical Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of PreveCeutical Medical Inc from 2016 to 2024. Review PreveCeutical Medical Inc (18H) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-6.64 Million ≈ $-7.76 Million |
€-426.69K ≈ $-498.85K |
0.064x | +25.09% |
| 2023-12-31 | €-5.78 Million ≈ $-6.76 Million |
€-296.97K ≈ $-347.19K |
0.051x | -47.18% |
| 2022-12-31 | €-4.64 Million ≈ $-5.42 Million |
€-450.99K ≈ $-527.25K |
0.097x | -6.35% |
| 2021-12-31 | €-4.10 Million ≈ $-4.80 Million |
€-426.39K ≈ $-498.49K |
0.104x | +679.67% |
| 2020-12-31 | €-3.60 Million ≈ $-4.21 Million |
€64.59K ≈ $75.52K |
-0.018x | -108.09% |
| 2019-12-31 | €-4.49 Million ≈ $-5.25 Million |
€-993.94K ≈ $-1.16 Million |
0.222x | -93.32% |
| 2018-12-31 | €-2.29 Million ≈ $-2.67 Million |
€-7.57 Million ≈ $-8.85 Million |
3.314x | -73.46% |
| 2017-12-31 | €-344.34K ≈ $-402.57K |
€-4.30 Million ≈ $-5.03 Million |
12.485x | +181.02% |
| 2016-12-31 | €-296.06K ≈ $-346.13K |
€-1.32 Million ≈ $-1.54 Million |
4.443x | -- |
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disor… Read more